



Baseline Characteristics

Infusion Arms



Patient Demographics by Infusion Arm*

| | EDTA Chelation (N= 839) | Placebo (N= 869) | All Patients (N=1708) |
|---|------------------------------------|-----------------------------|----------------------------------|
| Age (years) | 65 (59, 72) | 66 (59, 72) | 65 (59, 72) |
| Female | 152 (18%) | 147 (17%) | 299 (18%) |
| Ethnicity | | | |
| Hispanic or Latino | 22 (3%) | 29 (3%) | 51 (3%) |
| Not Hispanic or Latino | 817 (97%) | 840 (97%) | 1657 (97%) |
| Race | | | |
| Caucasian | 790 (94%) | 815 (94%) | 1605 (94%) |
| Black or African American | 29 (3%) | 31 (4%) | 60 (4%) |
| Asian | 10 (1%) | 18 (2%) | 28 (2%) |
| American Indian / Alaska native | 11 (1%) | 6 (1%) | 17 (1%) |
| Native Hawaiian or Other Pacific Islander | 3 (0%) | 3 (0%) | 6 (0%) |
| Minority (Hispanic or non-Caucasian) | 72 (9%) | 84 (10%) | 156 (9%) |
| Height (inches) | 69 (65, 71) | 68 (66, 71) | 69 (66, 71) |

(continued on next page)

* Median, 25th and 75th percentiles are reported for all continuous variables.



Patient Demographics by Infusion Arm*

| | EDTA Chelation (N= 839) | Placebo (N= 869) | All Patients (N=1708) |
|-----------------|------------------------------------|-----------------------------|----------------------------------|
| Weight (pounds) | 198 (173, 228) | 197 (172, 228) | 198 (172, 228) |
| Males | 203 (182, 232) | 201 (178, 230) | 202 (180, 231) |
| Females | 163 (142, 191) | 173 (146, 204) | 167 (145, 197) |
| BMI | 30 (27, 34) | 30 (27, 34) | 30 (27, 34) |

* Median, 25th and 75th percentiles are reported for all continuous variables.



Medical History by Infusion Arm

| | EDTA Chelation (N= 839) | Placebo (N= 869) | All Patients (N=1708) |
|--|--|-----------------------------|----------------------------------|
| Angina pectoris | 461 (55%) | 465 (54%) | 926 (54%) |
| Time from qualifying MI to randomization (years) | 4.3 (1.8, 9.1) | 4.8 (1.5, 9.5) | 4.6 (1.6, 9.2) |
| Anterior MI | 337 (40%) | 337 (39%) | 674 (39%) |
| Congestive heart failure | 154 (18%) | 153 (18%) | 307 (18%) |
| Valvular heart disease | 92 (11%) | 83 (10%) | 175 (10%) |
| Stroke | 57 (7%) | 54 (6%) | 111 (6%) |
| TIA | 42 (5%) | 42 (5%) | 84 (5%) |
| Diabetes | 265 (32%) | 273 (31%) | 538 (31%) |
| Peripheral vascular disease | 126 (15%) | 142 (16%) | 268 (16%) |
| Intermittent claudication | 66 (8%) | 78 (9%) | 144 (9%) |
| Severe intermittent claudication | 26 (3%) | 18 (2%) | 44 (3%) |

(continued on next page)



Medical History by Infusion Arm

| | EDTA Chelation (N= 839) | Placebo (N= 869) | All Patients (N=1708) |
|--|--|-----------------------------|----------------------------------|
| Hypertension | 568 (68%) | 601 (69%) | 1169 (68%) |
| Hypercholesterolemia | 676 (82%) | 694 (81%) | 1370 (82%) |
| Atrial fibrillation | 85 (10%) | 110 (13%) | 195 (12%) |
| Cardiac arrest or sustained ventricular tachycardia | 56 (7%) | 74 (9%) | 130 (8%) |
| Osteoporosis | 39 (5%) | 48 (6%) | 87 (5%) |
| Former cigarette smoker | 467 (56%) | 488 (56%) | 955 (56%) |
| Thyroid disease | 109 (13%) | 105 (12%) | 214 (13%) |
| Fracture(s) since age 50 | 44 (5%) | 68 (8%) | 112 (7%) |



Procedure History by Infusion Arm

| | EDTA Chelation (N= 839) | Placebo (N= 869) | All Patients (N=1708) |
|---|------------------------------------|-----------------------------|----------------------------------|
| CABG | 384 (46%) | 390 (45%) | 774 (45%) |
| PCI | 491 (59%) | 516 (59%) | 1007 (59%) |
| Any cardiac revascularization (CABG or PCI) | 694 (83%) | 720 (83%) | 1414 (83%) |
| Pacemaker | 53 (6%) | 62 (7%) | 115 (7%) |
| AICD | 46 (6%) | 54 (7%) | 100 (6%) |
| Revascularization of lower extremities | 34 (4%) | 38 (5%) | 72 (4%) |
| Revascularization of carotid arteries | 46 (6%) | 46 (6%) | 92 (6%) |



Presenting Characteristics by Infusion Arm *

| | EDTA Chelation (N= 839) | Placebo (N= 869) | All Patients (N=1708) |
|--|------------------------------------|-----------------------------|----------------------------------|
| Blood Pressure | | | |
| Systolic | 130 (120, 140) | 130 (120, 140) | 130 (120, 140) |
| Diastolic | 76 (70, 80) | 76 (70, 80) | 76 (70, 80) |
| Pulse (bpm) | 67 (60, 74) | 68 (60, 75) | 68 (60, 74) |
| Current Canadian Cardiovascular Society (CCS) angina class | | | |
| No angina | 650 (77%) | 674 (78%) | 1324 (78%) |
| Class I | 83 (10%) | 91 (10%) | 174 (10%) |
| Class II | 77 (9%) | 72 (8%) | 149 (9%) |
| Class III | 26 (3%) | 31 (4%) | 57 (3%) |
| Class IV | 3 (0%) | 1 (0%) | 4 (0%) |
| Current NYHA heart failure class | | | |
| No heart failure | 662 (79%) | 687 (79%) | 1349 (79%) |
| Class I | 102 (12%) | 108 (12%) | 210 (12%) |
| Class II | 63 (8%) | 59 (7%) | 122 (7%) |
| Class III | 12 (1%) | 15 (2%) | 27 (2%) |
| Class IV | 0 | 0 | 0 |

* Median, 25th and 75th percentiles are reported for all continuous variables.



Baseline Medications by Infusion Arm

| | EDTA Chelation (N= 839) | Placebo (N= 869) | All Patients (N=1708) |
|---------------------------|------------------------------------|-----------------------------|----------------------------------|
| Aspirin | 717 (85%) | 710 (82%) | 1427 (84%) |
| Type of enrolling center: | | | |
| Academic *, ** | 75 (89%) | 82 (87%) | 157 (88%) |
| Cardiology Office * | 195 (88%) | 186 (85%) | 381 (86%) |
| CAM & Cardiology Office * | 43 (81%) | 42 (75%) | 85 (78%) |
| CAM * | 404 (84%) | 400 (80%) | 804 (82%) |
| Beta-blocker | 611 (73%) | 615 (71%) | 1226 (72%) |
| Type of enrolling center: | | | |
| Academic *, ** | 70 (83%) | 79 (84%) | 149 (84%) |
| Cardiology Office * | 168 (76%) | 161 (73%) | 329 (75%) |
| CAM & Cardiology Office * | 41 (77%) | 41 (73%) | 82 (75%) |
| CAM * | 332 (69%) | 334 (67%) | 666 (68%) |

(continued on next page)

* The denominators for these percentages are the number of patients enrolled at each type of center.

** Includes 6 sites characterized as research institutions.



Baseline Medications by Infusion Arm

| | EDTA Chelation (N= 839) | Placebo (N= 869) | All Patients (N=1708) |
|---|------------------------------------|-----------------------------|----------------------------------|
| Statin | 615 (73%) | 633 (73%) | 1248 (73%) |
| Type of enrolling center: | | | |
| Academic *, ** | 70 (83%) | 82 (87%) | 152 (85%) |
| Cardiology Office * | 181 (82%) | 168 (76%) | 349 (79%) |
| CAM & Cardiology Office * | 25 (47%) | 34 (61%) | 59 (54%) |
| CAM * | 339 (70%) | 349 (70%) | 688 (70%) |
| Angiotensin converting enzyme inhibitor | 432 (51%) | 448 (52%) | 880 (52%) |
| Type of enrolling center: | | | |
| Academic *, ** | 49 (58%) | 55 (59%) | 104 (58%) |
| Cardiology Office * | 122 (55%) | 106 (48%) | 228 (52%) |
| CAM & Cardiology Office * | 20 (38%) | 24 (43%) | 44 (40%) |
| CAM * | 241 (50%) | 263 (53%) | 504 (51%) |

(continued on next page)

* The denominators for these percentages are the number of patients enrolled at each type of center.

** Includes 6 sites characterized as research institutions.



Baseline Medications by Infusion Arm

| | EDTA Chelation (N= 839) | Placebo (N= 869) | All Patients (N=1708) |
|------------------------------|------------------------------------|-----------------------------|----------------------------------|
| Angiotensin receptor blocker | 122 (15%) | 147 (17%) | 269 (16%) |
| Type of enrolling center: | | | |
| Academic *, ** | 16 (19%) | 21 (22%) | 37 (21%) |
| Cardiology Office * | 35 (16%) | 45 (20%) | 80 (18%) |
| CAM & Cardiology Office * | 8 (15%) | 8 (14%) | 16 (15%) |
| CAM * | 63 (13%) | 73 (15%) | 136 (14%) |
| ACE or ARB | 525 (63%) | 559 (64%) | 1084 (63%) |
| Alpha-blocker | 40 (5%) | 56 (7%) | 96 (6%) |
| Calcium channel blocker | 160 (20%) | 165 (20%) | 325 (20%) |
| Diuretic | 266 (33%) | 295 (35%) | 561 (34%) |
| Clopidogrel | 212 (26%) | 213 (25%) | 425 (26%) |
| Warfarin | 73 (9%) | 75 (9%) | 148 (9%) |

(continued on next page)

* The denominators for these percentages are the number of patients enrolled at each type of center.

** Includes 6 sites characterized as research institutions.



Baseline Medications by Infusion Arm

| | EDTA Chelation (N= 839) | Placebo (N= 869) | All Patients (N=1708) |
|----------------------------------|------------------------------------|-----------------------------|----------------------------------|
| Aspirin or warfarin | 746 (89%) | 756 (87%) | 1502 (88%) |
| Aspirin, warfarin or clopidogrel | 768 (92%) | 784 (90%) | 1552 (91%) |
| Amiodarone | 24 (3%) | 27 (3%) | 51 (3%) |
| Other antiarrhythmic drug | 11 (1%) | 24 (3%) | 35 (2%) |
| Digoxin | 50 (6%) | 61 (7%) | 111 (7%) |
| Diabetes medication | | | |
| Insulin | 73 (9%) | 87 (10%) | 160 (10%) |
| Oral hypoglycemic | 191 (24%) | 189 (23%) | 380 (23%) |
| Thyroid replacement therapy | 105 (13%) | 102 (12%) | 207 (13%) |
| Medication for PVD | | | |
| Pletal | 15 (2%) | 16 (2%) | 31 (2%) |
| Pentoxifylline | 4 (1%) | 6 (1%) | 10 (1%) |

(continued on next page)

* The denominators for these percentages are the number of patients enrolled at each type of center.

** Includes 6 sites characterized as research institutions.



Baseline Medications by Infusion Arm

| | EDTA Chelation (N= 839) | Placebo (N= 869) | All Patients (N=1708) |
|-----------------------------|------------------------------------|-----------------------------|----------------------------------|
| Medication for osteoporosis | 30 (4%) | 23 (3%) | 53 (3%) |
| Multivitamin | 356 (44%) | 359 (43%) | 715 (43%) |
| Other vitamins/minerals | 428 (52%) | 424 (50%) | 852 (51%) |
| Herbal products | 281 (34%) | 279 (34%) | 560 (34%) |

* The denominators for these percentages are the number of patients enrolled at each type of center.

** Includes 6 sites characterized as research institutions.



Baseline Laboratory Measures by Infusion Arm *

| | EDTA Chelation (N= 839) | Placebo (N= 869) | All Patients (N=1708) |
|--|------------------------------------|-----------------------------|----------------------------------|
| Glycosuria positive | 38 (5%) | 38 (4%) | 76 (5%) |
| Proteinuria positive | 51 (6%) | 76 (9%) | 127 (8%) |
| Hematuria positive | 32 (4%) | 44 (5%) | 76 (5%) |
| Glucose (mg/dL) | 103 (92, 121) | 102 (92, 121) | 102 (92, 121) |
| Creatinine (mg/dL) | 1.1 (0.9, 1.2) | 1.1 (0.9, 1.2) | 1.1 (0.9, 1.2) |
| Potassium (mmol/L) | 4.5 (4.2, 4.7) | 4.5 (4.2, 4.8) | 4.5 (4.2, 4.7) |
| Magnesium (mg/dL) | 2.0 (1.9, 2.1) | 2.0 (1.9, 2.1) | 2.0 (1.9, 2.1) |
| Calcium (mg/dL) | 9.4 (9.1, 9.6) | 9.4 (9.2, 9.7) | 9.4 (9.1, 9.6) |
| White blood cell count (x10 ³ cells/uL) | 6.5 (5.3, 7.6) | 6.4 (5.5, 7.6) | 6.5 (5.4, 7.6) |
| Hematocrit (%) | 43 (40, 45) | 43 (40, 45) | 43 (40, 45) |
| Platelet count (x10 ³ cells/uL) | 212 (181, 250) | 214 (178, 249) | 213 (179, 250) |
| Neutrophils (cells/uL) | 3905 (3021, 4787) | 3918 (3120, 4809) | 3912 (3085, 4792) |

(continued on next page)

* Median, 25th and 75th percentiles are reported for all continuous variables.



Baseline Laboratory Measures by Infusion Arm *

| | EDTA Chelation (N= 839) | Placebo (N= 869) | All Patients (N=1708) |
|-------------------------------------|------------------------------------|-----------------------------|----------------------------------|
| Total bilirubin (mg/dL) | 0.6 (0.5, 0.7) | 0.6 (0.5, 0.8) | 0.6 (0.5, 0.8) |
| Alkaline phosphatase (U/L) | 70 (58, 85) | 70 (58, 83) | 70 (58, 84) |
| AST (U/L) | 21 (18, 26) | 21 (17, 25) | 21 (17, 25) |
| ALT (U/L) | 21 (16, 28) | 21 (16, 27) | 21 (16, 27) |
| Total cholesterol (mg/dL) | 164 (139, 192) | 166 (143, 198) | 165 (141, 195) |
| HDL (mg/dL) | 43 (36, 52) | 43 (36, 50) | 43 (36, 51) |
| LDL (mg/dL) | 87 (66, 112) | 90 (68, 117) | 89 (67, 115) |
| Triglycerides (mg/dL) | 135 (94, 199) | 147 (99, 208) | 139 (96, 204) |
| Iron (mg/dL) | 87 (69, 108) | 85 (68, 107) | 86 (69, 107) |
| Total iron binding capacity (ug/dL) | 326 (296, 360) | 329 (303, 365) | 328 (299, 361) |
| % TIBC | 27 (21, 35) | 26 (20, 33) | 26 (21, 34) |
| C-reactive protein (mg/dL) | 0.5 (0.2, 1.9) | 0.6 (0.2, 2.2) | 0.6 (0.2, 2.0) |

* Median, 25th and 75th percentiles are reported for all continuous variables.



Baseline Characteristics

Vitamin Arms



Patient Demographics by Vitamin Arm *

| | Placebo (N= 855) | High-Dose Vitamins (N= 853) | All Patients (N=1708) |
|---|-----------------------------|--|----------------------------------|
| Age (years) | 65 (60, 72) | 65 (59, 72) | 65 (59, 72) |
| Female | 152 (18%) | 147 (17%) | 299 (18%) |
| Ethnicity | | | |
| Hispanic or Latino | 31 (4%) | 20 (2%) | 51 (3%) |
| Not Hispanic or Latino | 824 (96%) | 833 (98%) | 1657 (97%) |
| Race | | | |
| Caucasian | 808 (95%) | 797 (93%) | 1605 (94%) |
| Black or African American | 32 (4%) | 28 (3%) | 60 (4%) |
| Asian | 11 (1%) | 17 (2%) | 28 (2%) |
| American Indian / Alaska native | 4 (0%) | 13 (2%) | 17 (1%) |
| Native Hawaiian or Other Pacific Islander | 3 (0%) | 3 (0%) | 6 (0%) |
| Minority (Hispanic or non-Caucasian) | 78 (9%) | 78 (9%) | 156 (9%) |
| Height (inches) | 69 (66, 71) | 69 (66, 71) | 69 (66, 71) |

(continued on next page)

* Median, 25th and 75th percentiles are reported for all continuous variables.



Patient Demographics by Vitamin Arm *

| | Placebo (N= 855) | High-Dose Vitamins (N= 853) | All Patients (N=1708) |
|-----------------|-----------------------------|--|----------------------------------|
| Weight (pounds) | 199 (174, 229) | 196 (171, 226) | 198 (172, 228) |
| Males | 205 (181, 233) | 200 (179, 229) | 202 (180, 231) |
| Females | 168 (146, 199) | 166 (143, 195) | 167 (145, 197) |
| BMI | 30 (27, 34) | 29 (26, 33) | 30 (27, 34) |

* Median, 25th and 75th percentiles are reported for all continuous variables.



Medical History by Vitamin Arm

| | Placebo (N= 855) | High-Dose Vitamins (N= 853) | All Patients (N=1708) |
|--|-----------------------------|--|----------------------------------|
| Angina pectoris | 479 (56%) | 447 (52%) | 926 (54%) |
| Time from qualifying MI to randomization (years) | 4.6 (1.7, 9.0) | 4.5 (1.6, 9.5) | 4.6 (1.6, 9.2) |
| Anterior MI | 333 (39%) | 341 (40%) | 674 (39%) |
| Congestive heart failure | 170 (20%) | 137 (16%) | 307 (18%) |
| Valvular heart disease | 103 (12%) | 72 (9%) | 175 (10%) |
| Stroke | 55 (6%) | 56 (7%) | 111 (6%) |
| TIA | 41 (5%) | 43 (5%) | 84 (5%) |
| Diabetes | 256 (30%) | 282 (33%) | 538 (31%) |
| Peripheral vascular disease | 143 (17%) | 125 (15%) | 268 (16%) |
| Intermittent claudication | 76 (9%) | 68 (8%) | 144 (9%) |
| Severe intermittent claudication | 23 (3%) | 21 (3%) | 44 (3%) |

(continued on next page)



Medical History by Vitamin Arm

| | Placebo (N= 855) | High-Dose Vitamins (N= 853) | All Patients (N=1708) |
|--|-----------------------------|--|----------------------------------|
| Hypertension | 595 (70%) | 574 (67%) | 1169 (68%) |
| Hypercholesterolemia | 690 (82%) | 680 (81%) | 1370 (82%) |
| Atrial fibrillation | 115 (14%) | 80 (10%) | 195 (12%) |
| Cardiac arrest or sustained ventricular tachycardia | 70 (8%) | 60 (7%) | 130 (8%) |
| Osteoporosis | 41 (5%) | 46 (6%) | 87 (5%) |
| Former cigarette smoker | 468 (55%) | 487 (57%) | 955 (56%) |
| Thyroid disease | 107 (13%) | 107 (13%) | 214 (13%) |
| Fracture(s) since age 50 | 51 (6%) | 61 (7%) | 112 (7%) |



Procedure History by Vitamin Arm

| | Placebo (N= 855) | High-Dose Vitamins (N= 853) | All Patients (N=1708) |
|---|-----------------------------|--|----------------------------------|
| CABG | 384 (45%) | 390 (46%) | 774 (45%) |
| PCI | 523 (61%) | 484 (57%) | 1007 (59%) |
| Any cardiac revascularization (CABG or PCI) | 709 (83%) | 705 (83%) | 1414 (83%) |
| Pacemaker | 55 (7%) | 60 (7%) | 115 (7%) |
| AICD | 52 (6%) | 48 (6%) | 100 (6%) |
| Revascularization of lower extremities | 34 (4%) | 38 (5%) | 72 (4%) |
| Revascularization of carotid arteries | 44 (5%) | 48 (6%) | 92 (6%) |



Presenting Characteristics by Vitamin Arm *

| | Placebo (N= 855) | High-Dose Vitamins (N= 853) | All Patients (N=1708) |
|--|-----------------------------|--|----------------------------------|
| Blood Pressure | | | |
| Systolic | 130 (120, 140) | 130 (118, 140) | 130 (120, 140) |
| Diastolic | 76 (70, 80) | 76 (70, 81) | 76 (70, 80) |
| Pulse (bpm) | 68 (60, 74) | 66 (60, 74) | 68 (60, 74) |
| Current Canadian Cardiovascular Society (CCS) angina class | | | |
| No angina | 661 (77%) | 663 (78%) | 1324 (78%) |
| Class I | 88 (10%) | 86 (10%) | 174 (10%) |
| Class II | 80 (9%) | 69 (8%) | 149 (9%) |
| Class III | 24 (3%) | 33 (4%) | 57 (3%) |
| Class IV | 2 (0%) | 2 (0%) | 4 (0%) |
| Current NYHA heart failure class | | | |
| No heart failure | 664 (78%) | 685 (80%) | 1349 (79%) |
| Class I | 109 (13%) | 101 (12%) | 210 (12%) |
| Class II | 69 (8%) | 53 (6%) | 122 (7%) |
| Class III | 13 (2%) | 14 (2%) | 27 (2%) |
| Class IV | 0 | 0 | 0 |

* Median, 25th and 75th percentiles are reported for all continuous variables.



Baseline Medications by Vitamin Arm

| | Placebo (N= 855) | High-Dose Vitamins (N= 853) | All Patients (N=1708) |
|---------------------------|-----------------------------|--|----------------------------------|
| Aspirin | 698 (82%) | 729 (85%) | 1427 (84%) |
| Type of enrolling center: | | | |
| Academic *, ** | 79 (88%) | 78 (89%) | 157 (88%) |
| Cardiology Office * | 183 (83%) | 198 (90%) | 381 (86%) |
| CAM & Cardiology Office * | 40 (75%) | 45 (80%) | 85 (78%) |
| CAM * | 396 (80%) | 408 (84%) | 804 (82%) |
| Beta-blocker | 624 (73%) | 602 (71%) | 1226 (72%) |
| Type of enrolling center: | | | |
| Academic *, ** | 77 (86%) | 72 (82%) | 149 (84%) |
| Cardiology Office * | 172 (78%) | 157 (71%) | 329 (75%) |
| CAM & Cardiology Office * | 39 (74%) | 43 (77%) | 82 (75%) |
| CAM * | 336 (68%) | 330 (68%) | 666 (68%) |

(continued on next page)

* The denominators for these percentages are the number of patients enrolled at each type of center.

** Includes 6 sites characterized as research institutions.



Baseline Medications by Vitamin Arm

| | Placebo (N= 855) | High-Dose Vitamins (N= 853) | All Patients (N=1708) |
|---|-----------------------------|--|----------------------------------|
| Statin | 619 (72%) | 629 (74%) | 1248 (73%) |
| Type of enrolling center: | | | |
| Academic *, ** | 76 (84%) | 76 (86%) | 152 (85%) |
| Cardiology Office * | 173 (79%) | 176 (80%) | 349 (79%) |
| CAM & Cardiology Office * | 25 (47%) | 34 (61%) | 59 (54%) |
| CAM * | 345 (70%) | 343 (70%) | 688 (70%) |
| Angiotensin converting enzyme inhibitor | 441 (52%) | 439 (51%) | 880 (52%) |
| Type of enrolling center: | | | |
| Academic *, ** | 52 (58%) | 52 (59%) | 104 (58%) |
| Cardiology Office * | 111 (50%) | 117 (53%) | 228 (52%) |
| CAM & Cardiology Office * | 19 (36%) | 25 (45%) | 44 (40%) |
| CAM * | 259 (53%) | 245 (50%) | 504 (51%) |

(continued on next page)

* The denominators for these percentages are the number of patients enrolled at each type of center.

** Includes 6 sites characterized as research institutions.



Baseline Medications by Vitamin Arm

| | Placebo (N= 855) | High-Dose Vitamins (N= 853) | All Patients (N=1708) |
|------------------------------|-----------------------------|--|----------------------------------|
| Angiotensin receptor blocker | 145 (17%) | 124 (15%) | 269 (16%) |
| Type of enrolling center: | | | |
| Academic *, ** | 17 (19%) | 20 (23%) | 37 (21%) |
| Cardiology Office * | 40 (18%) | 40 (18%) | 80 (18%) |
| CAM & Cardiology Office * | 7 (13%) | 9 (16%) | 16 (15%) |
| CAM * | 81 (16%) | 55 (11%) | 136 (14%) |
| ACE or ARB | 555 (65%) | 529 (62%) | 1084 (63%) |
| Alpha-blocker | 55 (7%) | 41 (5%) | 96 (6%) |
| Calcium channel blocker | 166 (20%) | 159 (19%) | 325 (20%) |
| Diuretic | 286 (35%) | 275 (34%) | 561 (34%) |
| Clopidogrel | 225 (27%) | 200 (24%) | 425 (26%) |
| Warfarin | 88 (11%) | 60 (7%) | 148 (9%) |

(continued on next page)

* The denominators for these percentages are the number of patients enrolled at each type of center.

** Includes 6 sites characterized as research institutions.



Baseline Medications by Vitamin Arm

| | Placebo (N= 855) | High-Dose Vitamins (N= 853) | All Patients (N=1708) |
|----------------------------------|-----------------------------|--|----------------------------------|
| Aspirin or warfarin | 743 (87%) | 759 (89%) | 1502 (88%) |
| Aspirin, warfarin or clopidogrel | 771 (90%) | 781 (92%) | 1552 (91%) |
| Amiodarone | 31 (4%) | 20 (2%) | 51 (3%) |
| Other antiarrhythmic drug | 18 (2%) | 17 (2%) | 35 (2%) |
| Digoxin | 52 (6%) | 59 (7%) | 111 (7%) |
| Diabetes medication | | | |
| Insulin | 89 (11%) | 71 (9%) | 160 (10%) |
| Oral hypoglycemic | 173 (21%) | 207 (25%) | 380 (23%) |
| Thyroid replacement therapy | 106 (13%) | 101 (12%) | 207 (13%) |
| Medication for PVD | | | |
| Pletal | 18 (2%) | 13 (2%) | 31 (2%) |
| Pentoxifylline | 6 (1%) | 4 (0%) | 10 (1%) |

(continued on next page)

* The denominators for these percentages are the number of patients enrolled at each type of center.

** Includes 6 sites characterized as research institutions.



Baseline Medications by Vitamin Arm

| | Placebo (N= 855) | High-Dose Vitamins (N= 853) | All Patients (N=1708) |
|-----------------------------|-----------------------------|--|----------------------------------|
| Medication for osteoporosis | 23 (3%) | 30 (4%) | 53 (3%) |
| Multivitamin | 371 (45%) | 344 (42%) | 715 (43%) |
| Other vitamins/minerals | 424 (51%) | 428 (52%) | 852 (51%) |
| Herbal products | 295 (36%) | 265 (32%) | 560 (34%) |

* The denominators for these percentages are the number of patients enrolled at each type of center.

** Includes 6 sites characterized as research institutions.



Baseline Laboratory Measures by Vitamin Arm *

| | Placebo (N= 855) | High-Dose Vitamins (N= 853) | All Patients (N=1708) |
|--|-----------------------------|--|----------------------------------|
| Glycosuria positive | 38 (4%) | 38 (5%) | 76 (5%) |
| Proteinuria positive | 74 (9%) | 53 (6%) | 127 (8%) |
| Hematuria positive | 37 (4%) | 39 (5%) | 76 (5%) |
| Glucose (mg/dL) | 103 (93, 120) | 102 (92, 122) | 102 (92, 121) |
| Creatinine (mg/dL) | 1.1 (0.9, 1.2) | 1.1 (0.9, 1.2) | 1.1 (0.9, 1.2) |
| Potassium (mmol/L) | 4.5 (4.2, 4.7) | 4.5 (4.2, 4.8) | 4.5 (4.2, 4.7) |
| Magnesium (mg/dL) | 2.0 (1.9, 2.1) | 2.0 (1.9, 2.1) | 2.0 (1.9, 2.1) |
| Calcium (mg/dL) | 9.4 (9.1, 9.6) | 9.4 (9.2, 9.6) | 9.4 (9.1, 9.6) |
| White blood cell count (x10 ³ cells/uL) | 6.4 (5.4, 7.6) | 6.5 (5.4, 7.6) | 6.5 (5.4, 7.6) |
| Hematocrit (%) | 43 (40, 45) | 43 (40, 45) | 43 (40, 45) |
| Platelet count (x10 ³ cells/uL) | 214 (180, 250) | 212 (179, 249) | 213 (179, 250) |
| Neutrophils (cells/uL) | 3916 (3060, 4774) | 3911 (3118, 4809) | 3912 (3085, 4792) |

(continued on next page)

* Median, 25th and 75th percentiles are reported for all continuous variables.



Baseline Laboratory Measures by Vitamin Arm *

| | Placebo (N= 855) | High-Dose Vitamins (N= 853) | All Patients (N=1708) |
|-------------------------------------|-----------------------------|--|----------------------------------|
| Total bilirubin (mg/dL) | 0.6 (0.4, 0.7) | 0.6 (0.5, 0.8) | 0.6 (0.5, 0.8) |
| Alkaline phosphatase (U/L) | 70 (58, 83) | 70 (58, 85) | 70 (58, 84) |
| AST (U/L) | 21 (18, 25) | 21 (17, 25) | 21 (17, 25) |
| ALT (U/L) | 21 (16, 27) | 21 (16, 27) | 21 (16, 27) |
| Total cholesterol (mg/dL) | 166 (142, 197) | 164 (140, 193) | 165 (141, 195) |
| HDL (mg/dL) | 42 (36, 50) | 43 (37, 51) | 43 (36, 51) |
| LDL (mg/dL) | 89 (68, 117) | 88 (67, 113) | 89 (67, 115) |
| Triglycerides (mg/dL) | 138 (93, 202) | 141 (99, 206) | 139 (96, 204) |
| Iron (mg/dL) | 86 (67, 107) | 85 (69, 108) | 86 (69, 107) |
| Total iron binding capacity (ug/dL) | 326 (299, 363) | 329 (298, 360) | 328 (299, 361) |
| % TIBC | 26 (20, 34) | 26 (21, 33) | 26 (21, 34) |
| C-reactive protein (mg/dL) | 0.6 (0.2, 2.0) | 0.6 (0.2, 2.0) | 0.6 (0.2, 2.0) |

* Median, 25th and 75th percentiles are reported for all continuous variables.